Table 1. Demographics information and numbers of non-motor symptoms in NPRBD and PRBD groups.
NPRBD group | PRBD group | P | |
---|---|---|---|
Number (cases) | 143 | 67 | |
Male/Total [cases/total (%)] | 77/143 (53.85%) | 38/67 (56.72%) | 0.697 |
Age [years, median (quartile)] | 59.59 ± 10.63 | 60.91 ± 11.69 | 0.464 |
Age of disease onset (years, mean ± SD) | 56.60 ± 11.36 | 55.93 ± 11.72 | 0.702 |
Disease duration [years, median (quartile)] | 2.00 (1.00~4.00) | 3.00 (1.35~6.00) | 0.004 ** |
Hoehn-Yahr stage [stage, median (quartile)] | 1.50 (1.50~2.50) | 2.00 (1.50~2.50) | 0.040 * |
UPDRS III [points, mean ± SD] | 22.18 ± 9.271 | 28.59 ± 15.218 | 0.005 ** |
Clinical phenotype [cases/total (%)] | |||
Tremor type | 44/143 (30.77%) | 14/67 (20.90%) | 0.136 |
Rigidity-bradykinesia type | 17/143 (11.89%) | 16/67 (23.88%) | 0.026 * |
Mixed type | 82/143 (57.34%) | 37/67 (55.22%) | 0.773 |
Total numbers of NMS (cases, mean ± SD) | 8.41 ± 5.27 | 11.17 ± 5.96 | 0.005 ** |
Numbers of pre-MS NMS [cases, median (quartile)] | 1.00 (0~3.00) | 2.00 (0.00~4.50) | 0.083 |
Numbers of post-MS NMS [cases, median (quartile)] | 5.00 (2.00~10.00) | 7.00 (3.25~12.00) | 0.067 |
Levodopa equivalent dose(mg, mean ±SD) | 312.87 ± 101.67 | 331.12 ± 87.76 | 0.601 |
*: P<0.05,
**: P<0.01.